While Bloomberg News first reported the selection, the administration has yet to issue a formal confirmation. Other major news organizations, including Reuters, have not independently verified the appointment, leaving the status of the nomination in a state of administrative flux.
Overton’s ascent from internal policy circles to the helm of a major regulatory agency reflects the administration’s focus on installing loyalist oversight across federal departments. If confirmed, she will inherit a massive portfolio overseeing clinical trial approvals, food safety standards, and the fast-moving landscape of pharmaceutical regulation.
Comments (0)
No comments yet. Be the first!